TY  - BOOK
AU  - Escors,David
AU  - Talmadge,James E.
AU  - Breckpot,Karine
AU  - Van Ginderachter,Jo A.
AU  - Kochan,Grazyna
ED  - SpringerLink (Online service)
TI  - Myeloid-Derived Suppressor Cells and Cancer
T2  - SpringerBriefs in Immunology,
SN  - 9783319268217
AV  - QR180-189.5 
U1  - 616.079 23
PY  - 2016///
CY  - Cham
PB  - Springer International Publishing, Imprint: Springer
KW  - Medicine
KW  - Cancer research
KW  - Immunology
KW  - Oncology
KW  - Cell biology
KW  - Biomedicine
KW  - Cancer Research
KW  - Cell Biology
N1  - Controversies in Neoplastic Myeloplasia -- Differentiation of Murine Myeloid-derived Suppressor Cells -- Human MDSCs -- Ex Vivo MDSC Differentiation Models -- Immunoregulatory myeloid cells in the tumor microenvironment -- Signal Transducer and Activation of Transcription 3: A Master Regulator of Myeloid-derived Suppressor Cells -- Future Perspectives
N2  - The book starts with an introduction to and history of myeloid-derived suppressor cells (MDSCs), followed by a description of their differentiation, their role in the tumour microenvironment and their therapeutic targeting. It closes with an outlook on future developments. In cancer patients, myelopoiesis is perturbed and instead of generating immunogenic myeloid cells (such as dendritic cells, inflammatory macrophages and granulocytes), there is an increase in highly immature MDSCs. These cells are distributed systemically, resulting in general immunosuppression. They also infiltrate tumours, promoting their progression and metastasis by inhibiting the natural anti-tumour immune response. As these cells also interact with classical anti-neoplastic treatments, they have become major therapeutic targets in the pharmaceutical industry and in oncology research
UR  - http://148.231.10.114:2048/login?url=http://dx.doi.org/10.1007/978-3-319-26821-7
ER  -